SGMT
insider transactionsSagimet Biosciences Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
39.6K sh
Own New
-
Grant·A
Director
$0
39.6K sh
Own New
-
Grant·A
Director
$0
39.6K sh
Own New
-
Grant·A
Director
$0
39.6K sh
Own New
-
Grant·A
Director
$0
39.6K sh
Own New
-
Grant·A
Director
$0
39.6K sh
Own New
-
Grant·A
Chief Legal & Admin. Officer
$0
100.0K sh
Own New
-
Grant·A
David Happel KEY
President & CEO
$0
300.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
35.0K sh
Own New
-
Grant·A
Thierry Chauche KEY
Chief Financial Officer
$0
50.0K sh
Own New
-
Grant·A
Director
$0
17.1K sh
Own New
-
Grant·A
Chief Medical Officer
$0
264.8K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 12, 2026 | Beth C Seidenberg | Grant A | 39.6K | $0 |
| Jun 12, 2026 | Anne M. Phillips | Grant A | 39.6K | $0 |
| Jun 12, 2026 | George Kemble | Grant A | 39.6K | $0 |
| Jun 12, 2026 | Jennifer Jarrett | Grant A | 39.6K | $0 |
| Jun 12, 2026 | Paul W. Hoelscher | Grant A | 39.6K | $0 |
| Jun 12, 2026 | Elizabeth A Grammer | Grant A | 39.6K | $0 |
| May 28, 2026 | Elizabeth Rozek | Grant A | 100.0K | $0 |
| May 28, 2026 | David Happel KEY | Grant A | 300.0K | $0 |
| May 28, 2026 | Andreas Grauer | Grant A | 35.0K | $0 |
| May 28, 2026 | Thierry Chauche KEY | Grant A | 50.0K | $0 |
| May 21, 2026 | Beth C Seidenberg | Grant A | 17.1K | $0 |
| Apr 20, 2026 | Andreas Grauer | Grant A | 264.8K | $0 |
About SGMT insider trading
This page tracks insider transactions for Sagimet Biosciences Inc. (SGMT) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.